- Home
- A-Z Publications
- Current Medicinal Chemistry
- Previous Issues
- Volume 18, Issue 27, 2011
Current Medicinal Chemistry - Volume 18, Issue 27, 2011
Volume 18, Issue 27, 2011
-
-
Editorial [Hot Topic: Aptamers: Versatile Agents for Biomedical Applications (Guest Editor: Weibo Cai)]
By Weibo CaiAptamers, typically selected through systematic evolution of ligands by exponential enrichment (SELEX), have quickly emerged as a versatile class of agents with tremendous potential for a wide range of biomedical applications. Often regarded as “chemical antibodies”, aptamers can fold into well-defined 3D structures and bind to their target molecules with high affinity and specificity. To date, aptamers have been selected aga Read More
-
-
-
Aptamers Against Cell Surface Receptors: Selection, Modification and Application
More LessAptamers are synthetic oligonucleotides selected from pools of random-sequence oligonucleotides which bind to a wide range of biomolecular targets with high affinity and specificity. Compared with antibodies, aptamers exhibit significant advantages including small size, easy synthesis and modification, as well as low immunogenicity. Many of the aptamers also show inhibition of their targets, making them potential therapeu Read More
-
-
-
Recent Developments in Protein and Cell-Targeted Aptamer Selection and Applications
Authors: Jun Liu, Mingxu You, Ying Pu, Huixia Liu, Mao Ye and Weihong TanBecause of their easily modified chemical structures and wide range of targets, aptamers are ideal candidates for various applications, such as biomarker discovery, target diagnosis, molecular imaging, and drug delivery. Aptamers are oligonucleotide sequences that can bind to their targets specifically via unique three dimensional (3-D) structures. Usually, aptamers are obtained from repeated rounds of in vitro or in vivo sele Read More
-
-
-
Improving the Stability of Aptamers by Chemical Modification
Authors: R. E. Wang, H. Wu, Y. Niu and J. CaiEver since the invention of SELEX (systematic evolution of ligands by exponential enrichment), there has been rapid development for aptamers over the last two decades, making them a promising approach in therapeutic applications as either drug candidates or diagnostic tools. For therapeutic purposes, a durable performance of aptamers in biofluids is required, which is, however, hampered by the lack of stability o Read More
-
-
-
Nucleic Acid Aptamers Against Proteases
Authors: D. M. Dupont, L. M. Andersen, K. A. Botkjaer and P. A. AndreasenProteases are potential or realized therapeutic targets in a wide variety of pathological conditions. Moreover, proteases are classical subjects for studies of enzymatic and regulatory mechanisms. We here review the literature on nucleic acid aptamers selected with proteases as targets. Designing small molecule protease inhibitors of sufficient specificity has proved a daunting task. Aptamers seem to represent a promisin Read More
-
-
-
Nucleic Acid Aptamers Against Protein Kinases
Authors: L. Cerchia and V. de FranciscisDeregulation of kinase function has been implicated in several important diseases, including cancer, neurological and metabolic disorders. Because of their key role in causing disease, kinases have become one of the most intensively pursued classes of drug targets. To date, several monoclonal antibodies (mAbs) and small-molecule inhibitors have been approved for the treatment of cancer. Aptamers are short structured single Read More
-
-
-
Aptamers: Selection, Modification and Application to Nervous System Diseases
Authors: Y. Yang, X. Ren, H. J. Schluesener and Z. ZhangAptamers are nonnaturally occurring oligonucleotides generated by the SELEX (Systematic Evolution of Ligands by Exponential enrichment) process. Due to their unique three-dimensional structures, aptamers can bind to various targets, ranging from small compounds to cells and tissues, with high affinity and specificity. While first reported in 1990, aptamers have become useful tools in the biomedical field because Read More
-
-
-
Aptamers as Therapeutics in Cardiovascular Diseases
More LessWith many advantages over other therapeutic agents such as monoclonal antibodies, aptamers have recently emerged as a novel and powerful class of ligands with excellent potential for diagnostic and therapeutic applications. Typically generated through Systematic Evolution of Ligands by EXponential enrichment (SELEX), aptamers have been selected against a wide range of targets such as proteins, phospholipids, sugars, Read More
-
-
-
Aptamer-Based Fluorescent Biosensors
Authors: R. E. Wang, Y. Zhang, J. Cai, W. Cai and T. GaoSelected from random pools of DNA or RNA molecules through systematic evolution of ligands by exponential enrichment (SELEX), aptamers can bind to target molecules with high affinity and specificity, which makes them ideal recognition elements in the development of biosensors. To date, aptamer-based biosensors have used a wide variety of detection techniques, which are briefly summarized in this article. The focus of th Read More
-
-
-
Tumor-Targeted Drug Delivery with Aptamers
More LessCancer is one of the leading causes of death around the world. Tumor-targeted drug delivery is one of the major areas in cancer research. Aptamers exhibit many desirable properties for tumor-targeted drug delivery, such as ease of selection and synthesis, high binding affinity and specificity, low immunogenicity, and versatile synthetic accessibility. Over the last several years, aptamers have quickly become a new c Read More
-
-
-
Molecular Imaging with Nucleic Acid Aptamers
More LessWith many desirable properties such as ease of synthesis, small size, lack of immunogenicity, and versatile chemistry, aptamers represent a class of targeting ligands that possess tremendous potential in molecular imaging applications. Non-invasive imaging of various disease markers with aptamer-based probes has many potential clinical applications such as lesion detection, patient stratification, treatment monitoring, etc. Read More
-
-
-
Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Authors: X. Ni, M. Castanares, A. Mukherjee and S.E. LupoldAptamers are a special class of nucleic acid molecules that are beginning to be investigated for clinical use. These small RNA/DNA molecules can form secondary and tertiary structures capable of specifically binding proteins or other cellular targets; they are essentially a chemical equivalent of antibodies. Aptamers have the advantage of being highly specific, relatively small in size, and non-immunogenic. Since the discovery Read More
-
-
-
Peptide Aptamers with Biological and Therapeutic Applications
Authors: J. Li, S. Tan, X. Chen, C.-Y. Zhang and Y. ZhangPeptide aptamers are combinatorial protein molecules with specific bind affinity to given target proteins under intracellular conditions. The typical structure of peptide aptamers is a short peptide region inserted within a scaffold protein. The short peptide region is responsible for binding with its target protein and the scaffold protein helps to enhance the binding affinity and specificity through restriction on the conformation of th Read More
-
-
-
Current Trends in β-Lactam Based β-Lactamases Inhibitors
Authors: S. Biondi, S. Long, M. Panunzio and W. L. QinThe introduction of antibiotics to treat bacterial infections either by killing or blocking their growth has been accompanied by the development of resistance mechanism that allows the bacteria to survive and proliferate. In particular the successive series of β- lactams have selected several generations of β-lactamases including ESBLs, AmpC β-lactamases, KPC carbapenamases in Enterobacteriaceae, the metallo β-lactamas Read More
-
-
-
Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
Authors: L. Gatti, G. Cossa, G. L. Beretta, N. Zaffaroni and P. PeregoATP-binding cassette (ABC) transporters are a large family of proteins implicated in physiological cellular functions. Selected components of the family play a well-recognized role in extruding conventional cytotoxic antitumor agents and molecularly targeted drugs from cells. Some lines of evidence also suggest links between transporters and tumor cell survival, in part unrelated to efflux. However, the study of the precise Read More
-
-
-
Targeting Heat Shock Proteins 70/90 and Proteasome for Cancer Therapy
By R. E. WangRecent progresses in cancer therapy suggest the importance of targeting more than one protein targets or signaling pathways. In events of stresses including the therapeutic treatments, damaged proteins are either repaired by heat shock proteins or ubiquitin-tagged for proteasome-dependent protein degradation. Heat shock proteins mediated protein protection and cell signaling, as well as the ubiquitin- proteasoma Read More
-
Volumes & issues
-
Volume 32 (2025)
-
Volume 31 (2024)
-
Volume 30 (2023)
-
Volume 29 (2022)
-
Volume 28 (2021)
-
Volume 27 (2020)
-
Volume 26 (2019)
-
Volume 25 (2018)
-
Volume 24 (2017)
-
Volume 23 (2016)
-
Volume 22 (2015)
-
Volume 21 (2014)
-
Volume 20 (2013)
-
Volume 19 (2012)
-
Volume 18 (2011)
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 17 (2010)
-
Volume 16 (2009)
-
Volume 15 (2008)
-
Volume 14 (2007)
-
Volume 13 (2006)
-
Volume 12 (2005)
-
Volume 11 (2004)
-
Volume 10 (2003)
-
Volume 9 (2002)
-
Volume 8 (2001)
-
Volume 7 (2000)
Most Read This Month
Article
content/journals/cmc
Journal
10
5
false
en
